GLP-1 Receptor Agonists and Cardiovascular Effects

Receptor Distribution and Direct Cardiovascular Effects

• GLP-1 receptors are localized primarily to the sinoatrial node in the heart, providing direct chronotropic effects 1, 3
• GLP-1 receptors in arterial walls are critical for endothelial function and autonomic nervous system regulation, serving as the primary site for vasodilatory effects 1, 4

Mechanisms of Increased Cardiac Output

• In patients with acute MI and LV dysfunction, 72-hour GLP-1 infusion demonstrated improvement in both regional and global LV function 2
• In patients with NYHA class III-IV heart failure, 5-week GLP-1 infusion increased ejection fraction, exercise capacity, and quality of life 2
• In patients with diabetes and HFrEF, exenatide increased cardiac index and decreased pulmonary capillary wedge pressure compared to placebo 2, 5

Integrated Cardioprotective Mechanisms

• Improved myocardial substrate utilization enhances cardiac efficiency 1, 6
• Anti-inflammatory and anti-atherosclerotic effects reduce vascular resistance over time 1, 6
• Reduced myocardial ischemia injury protects cardiac function during stress 1, 6
• Lower systemic and pulmonary vascular resistance directly reduces cardiac afterload 1, 7
• Enhanced natriuresis and reduced albuminuria improve volume status and reduce cardiac preload 5

Important Clinical Caveats

• GLP-1 agonists increase heart rate by 3-10 beats/min due to direct effects on the sinoatrial node 5
• If symptomatic tachycardia or arrhythmia occurs, monitor and consider beta blockers 7, 8
• The American Heart Association recommends avoiding GLP-1 receptor agonists if recent HF decompensation 2
• GLP-1 agonists lower systolic blood pressure by 2-3 mm Hg, an effect largely independent of weight loss 5